Cantor Fitzgerald Predicts Nyxoah FY2026 Earnings

Nyxoah S.A. (NASDAQ:NYXH - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Nyxoah in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings per share of ($1.56) for the year. The consensus estimate for Nyxoah's current full-year earnings is ($1.91) per share.

A number of other equities analysts have also recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price target on shares of Nyxoah in a research note on Tuesday, April 8th. Stifel Nicolaus dropped their target price on Nyxoah from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Monday, April 21st.

Nyxoah Trading Down 0.3%

Shares of NYXH traded down $0.02 during midday trading on Tuesday, hitting $7.54. The stock had a trading volume of 16,252 shares, compared to its average volume of 75,508. Nyxoah has a 1 year low of $5.55 and a 1 year high of $11.87. The firm has a market cap of $256.81 million, a PE ratio of -4.03 and a beta of 1.65. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95. The stock's 50 day moving average is $6.75 and its 200 day moving average is $8.45.

Nyxoah (NASDAQ:NYXH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.14). The company had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.64 million. Nyxoah had a negative return on equity of 51.68% and a negative net margin of 1,043.93%.

Institutional Trading of Nyxoah

Institutional investors and hedge funds have recently made changes to their positions in the business. Kovack Advisors Inc. increased its stake in Nyxoah by 16.5% in the 1st quarter. Kovack Advisors Inc. now owns 23,295 shares of the company's stock worth $163,000 after buying an additional 3,295 shares during the period. Vestal Point Capital LP bought a new position in Nyxoah in the 4th quarter worth about $23,394,000. Ameriprise Financial Inc. purchased a new position in shares of Nyxoah during the fourth quarter worth approximately $135,000. Walleye Capital LLC raised its stake in shares of Nyxoah by 23.9% during the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after acquiring an additional 2,862 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Nyxoah in the fourth quarter valued at approximately $187,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.